Safety and Tolerability of Repeat Courses of IM Alefacept

Exclusion Criteria

• •Unstable erthrodermic or pustular psoriasis.
• •Diagnosis of guttate psoriasis.
• •Serious local infection or systemic infection within 3 months prior to first dose of alefacept.
• •Positive for HIV antibody.
• •Known invasive malignancy within 5 years of enrollment. Patients with a history of treated squamous cell and/or basal cell carcinomas limited to the skin are not excluded.
• •Evidence of active tuberculosis.
• •Current treatment for active tuberculosis or tuberculosis prophylaxis.
• •Female patients unwilling to practice effective contraception as defined by the investigator.
• •Female patients who are pregnant or breast-feeding.
• •Current enrollment in any other investigational drug study.
• •Previous participation in this study or previous alefacept studies.